Horizon Discovery have developed their 3D OncoSignature™ spheroid screening service that consists of a panel of 200 cell lines. In this application note they demonstrate the ability of parallel 2D and 3D OncoSignature primary screens to identify known compounds with enhanced activity under 3D conditions.
List view / Grid view
Filter the results
Sign up for free weekly 5-10 min videos from Horizon’s expert cell line engineers to help you improve your CRISPR editing experiments.
On-demand webinar: Leveraging advances in predesigned synthetic sgRNA for highly functional and specific CRISPR-Cas9 gene knockout
This webinar explains how synthetic guide RNAs are stable, eliminate cloning and sequencing steps, and avoid innate immune responses and cytotoxicity.
The clinical success rate of new oncology drugs is low compared to other diseases. One contributing factor is likely to be the testing systems used, particularly two-dimensional (2D) monolayer assay formats, which are the traditional mainstay of high-throughput compound screening.
This article explains how to plan a gene-editing experiment. How to choose your biological system and what reagents to get for your experimental aim.
Modify the genome and modulate expression of genes within human iPS cells with Dharmacon™ Edit-R CRISPR reagents.
Untangling gene expression complexity with pooled CRISPR screens coupled to single-cell transcriptome analysis
4 September 2020 | By Horizon Discovery
Join us on 4 November where we will present data showing how Horizon’s CRISPRsc screening platform offers a streamlined approach to elucidating valuable and intriguing biological information that is critical to resolving complex biological questions.
15 June 2020 | By Horizon Discovery
Watch our on-demand webinar with Horizon Discovery which summarises the challenges in translating promising pre-clinical therapeutic candidates into clinical success.
The high-throughput screening (HTS) facility at the Francis Crick Institute in the UK provides a core service for Crick research groups. It enables scientists to use large-scale, unbiased screening technologies and approaches as part of their research. Nikki Withers spoke to the Science Technology Platform Head, Michael Howell, to hear…
High-throughput screening is a common method of identifying lead compounds for drug development. The most common targets are enzymes – catalytic proteins that perform chemical reactions in the cell. In this article, Matthew Lloyd discusses the opportunities and challenges associated with this approach.
Exploring large databases and selecting compounds of interest can be extremely time-consuming for researchers. Here, Sacha Javor, Horst Flotow and Jingwen Shi discuss a novel chemoinformatics approach for drug discovery.
Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
The identification and validation of novel drug targets is a challenging process for drug discovery programmes.